# EMQN > EMQN offers external quality assessment, or proficiency testing, and knowledge, to help molecular diagnostic provides give the optimal service to patients Generated by Yoast SEO v28.2, this is an llms.txt file, meant for consumption by LLMs. ## Pages - [Privacy Policy](https://www.emqn.org/privacy-policy/) - [ESHG 2026](https://www.emqn.org/eshg2026/) - [Our EQA Schemes](https://www.emqn.org/our-eqa-schemes/) - [Discounts for Evolving Economies](https://www.emqn.org/discounts-for-evolving-economies/) - [Assessor Vacancies](https://www.emqn.org/assessor-vacancies/) ## Posts - [CADDA Knowledge Transfer Vouchers Funding Awarded](https://www.emqn.org/cadda-funding-emqn-project-selected/) - [EMQN Shortlisted for Quality Assurance and Control Award at the Pharma Industry Awards](https://www.emqn.org/emqn-shortlisted-for-quality-assurance-and-control-award-at-the-pharma-industry-awards/) - [EMQN Named Among Top 50 Inspiring Workplaces in the UK \& Ireland 2026](https://www.emqn.org/emqn-named-among-top-50-inspiring-workplaces-in-the-uk-ireland-2026/) - [EMQN Named Finalist in the 2026 UK \& Ireland Inspiring Workplaces Awards](https://www.emqn.org/emqn-named-finalist-in-the-2026-uk-ireland-inspiring-workplaces-awards/) - [EMQN and Ridacom Join Forces to Elevate Genomics Quality in Southeast Europe](https://www.emqn.org/emqn-and-ridacom-join-forces-to-elevate-genomics-quality-in-southeast-europe/) ## Best Practices - [EMQN Best Practice Guidelines for Genetic Testing and Reporting in RYR1\-related disorders](https://www.emqn.org/best-practice/emqn-best-practice-guidelines-for-genetic-testing-and-reporting-in-ryr1-related-disorders/): In 2008 the European Molecular Genetics Quality Network \(EMQN\) for the first time offered a European\-wide external quality assessment scheme for CAH \(due to 21\-OH deficiency\)\. - [Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5\-year perspective from an EQA provider](https://www.emqn.org/best-practice/uptake-of-dpyd-and-ugt1a1-testing-in-italy-and-adherence-to-pharmacogenetic-guidelines-a-5-year-perspective-from-an-eqa-provider/): In 2008 the European Molecular Genetics Quality Network \(EMQN\) for the first time offered a European\-wide external quality assessment scheme for CAH \(due to 21\-OH deficiency\)\. - [EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours](https://www.emqn.org/best-practice/emqn-best-practice-guidelines-for-analysis-and-reporting-of-microsatellite-instability-in-solid-tumours/): In 2008 the European Molecular Genetics Quality Network \(EMQN\) for the first time offered a European\-wide external quality assessment scheme for CAH \(due to 21\-OH deficiency\)\. - [EMQN: genetic testing in inherited heart conditions](https://www.emqn.org/best-practice/inherited-cardiomyopathies-and-arrhythmias/): Inherited cardiomyopathies and arrhythmias \(ICAs\) are a prevalent and clinically heterogeneous group of genetic disorders that are associated with increased risk of sudden cardiac death and heart failure\. - [EMQN: validation of clinical molecular genetic tests](https://www.emqn.org/best-practice/validation-and-verification-of-clinical-molecular-genetic-tests-externalemqn-validation-molecular-genetic-tests/): Funded by Eurogentest and by the UK Department of Health\. EMQN contributed to this work\. ## Events - [European Congress of Pathology](https://www.emqn.org/event/european-congress-of-pathology/) - [ESHG European Human Genetics Conference 2026](https://www.emqn.org/event/eshg-european-human-genetics-conference-2026/) - [CCMG \& Garrod 2026 Joint Conference](https://www.emqn.org/event/ccmg-garrod-2026-joint-conference/) ## Schemes - [Device verification samples for CYP2C19 \(POCT\) \- 2 SETS](https://www.emqn.org/scheme/device-verification-samples-for-cyp2c19-poct-2-sets/): Two sets of 8 patient\-like swab\-based materials designed to help implement and verify POCT devices for CYP2C19 testing\. See https://www\.emqn\.org/our\-eqa\-schemes/poct/ for more information\. - [Device verification samples for MT\-RNR1 \(POCT\) \- 2 SET](https://www.emqn.org/scheme/device-verification-samples-for-mt-rnr1-poct-2-set/): Two sets of 8 patient\-like swab\-based materials designed to help implement and verify POCT devices for MT\-RNR1 testing\. See https://www\.emqn\.org/our\-eqa\-schemes/poct/ for more information\. - [Lung Cancer \(NSCLC\) \[Tissue\]](https://www.emqn.org/scheme/lung-cancer-nsclc-tissue/): This EQA has two modules: COMMON BIOMARKERS \(mandatory to participate in this EQA\) and NEW \& EMERGING BIOMARKERS \(optional to participate in this EQA\) both using FFPE to test\. - [Lung Cancer \(NSCLC\) \[Plasma\]](https://www.emqn.org/scheme/lung-cancer-nsclc-plasma/): EGFR, BRAF and KRAS testing of cfDNA \(plasma\) for NSCLC\. This EQA is sponsored\. - [Urothelial/bladder cancer \(FGFR SNV/fusions\) \[Tissue\]](https://www.emqn.org/scheme/urothelial-bladder-cancer-fgfr-snv-fusions-tissue/): FGFR3 testing \(SNVs and gene fusions\) in Urothelial / Bladder cancer \(FFPE\) ## Categories - [Genomic \& inherited disorders](https://www.emqn.org/category/genomic-and-inherited-disorders/) - [Uncategorized](https://www.emqn.org/category/uncategorized/) - [Molecular Pathology](https://www.emqn.org/category/molecular-pathology/) - [Point\-of\-care testing](https://www.emqn.org/category/point-of-care-testing/) - [Technical Assessment](https://www.emqn.org/category/technical-assessment/) ## Document types - [Scientific publications](https://www.emqn.org/document-type/scientific-publications/) ## News categories - [Genomic and inherited disorders](https://www.emqn.org/news-category/genomic-and-inherited-disorders/) - [Point of care testing](https://www.emqn.org/news-category/point-of-care-testing/) ## Organisation category - [Staff](https://www.emqn.org/organisation-category/staff/) - [SSAB](https://www.emqn.org/organisation-category/ssab/) - [Company board](https://www.emqn.org/organisation-category/company-board/) ## Publication Categories - [Molecular Pathology](https://www.emqn.org/publication-category/molecular-pathology/) - [Genomic \& Inherited Disorders](https://www.emqn.org/publication-category/genomic-inherited-disorders/) - [Sequencing \(NGS and Sanger\)](https://www.emqn.org/publication-category/sequencing-ngs-and-sanger/) - [Non\-invasive Prenatal Testing \(NIPT\)](https://www.emqn.org/publication-category/non-invasive-prenatal-testing-nipt/) - [Pharmacogenetics](https://www.emqn.org/publication-category/pharmacogenetics/) ## Publication Types - [Poster](https://www.emqn.org/publication-type/poster/) - [White Paper](https://www.emqn.org/publication-type/white-paper/) ## Scheme Types - [Genomic and Inherited Disorders](https://www.emqn.org/scheme-type/genomic-and-inherited-disorders/) - [Molecular Pathology](https://www.emqn.org/scheme-type/molecular-pathology/) - [Point of Care Testing \(POCT\)](https://www.emqn.org/scheme-type/point-of-care-testing-poct/) - [Sequencing \(NGS and Sanger\)](https://www.emqn.org/scheme-type/sequencing-ngs-and-sanger/) - [Pre\-analytical processes](https://www.emqn.org/scheme-type/pre-analytical-processes/) ## Languages - [English](https://www.emqn.org/scheme-language/english/) - [German](https://www.emqn.org/scheme-language/german/) - [French](https://www.emqn.org/scheme-language/french/) - [Italian](https://www.emqn.org/scheme-language/italian/) - [Spanish](https://www.emqn.org/scheme-language/spanish/) ## Technologies - [NGS](https://www.emqn.org/scheme-technologies/ngs/) - [PCR based](https://www.emqn.org/scheme-technologies/pcr-based/) - [Panel testing](https://www.emqn.org/scheme-technologies/panel-testing/) - [CNV](https://www.emqn.org/scheme-technologies/cnv/) - [MLPA](https://www.emqn.org/scheme-technologies/mlpa/) ## Sample Types - [DNA in TE Buffer](https://www.emqn.org/scheme-sample-types/dna-in-te-buffer/) - [Artificial Buccal Swab](https://www.emqn.org/scheme-sample-types/artificial-buccal-swab/) - [FFPE](https://www.emqn.org/scheme-sample-types/ffpe/) - [Plasma cfDNA](https://www.emqn.org/scheme-sample-types/plasma-cfdna/) - [Online virtual cases](https://www.emqn.org/scheme-sample-types/online-virtual-cases/) ## Accreditations - [Yes](https://www.emqn.org/scheme-accreditation/yes/) - [No](https://www.emqn.org/scheme-accreditation/no/) - [Pending](https://www.emqn.org/scheme-accreditation/pending/) ## Keywords - [Molecular Genetics](https://www.emqn.org/scheme-keywords/molecular-genetics/) - [Cancer](https://www.emqn.org/scheme-keywords/cancer/) - [Panel testing](https://www.emqn.org/scheme-keywords/panel-testing/) - [Pharmacogenetics](https://www.emqn.org/scheme-keywords/pharmacogenetics/) - [Drug efficacy](https://www.emqn.org/scheme-keywords/drug-efficacy/) ## Optional - [Sitemap index](https://www.emqn.org/sitemap_index.xml)